Drugs / BAT8001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04189211 | Mar 2017 → Dec 2019 | carcinoma | Bio-Thera Solutions | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04151329 | Jun 2019 → Dec 2020 | cancer | Bio-Thera Solutions | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04185649 | Jul 2018 → Jul 2020 | HER2 positive breast carcinoma | Bio-Thera Solutions | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT8001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04185649 ↗ |
| Modality | Monoclonal antibody | “Recombinant Humanized Anti-HER2 Monoclonal Antibody-Maytansine Conjugate for Injection” NCT04189211 ↗ |
| Route | Intravenous | “2.4mg/kg IV infusions” NCT04151329 ↗ |